Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies-Reference-Cited by-同舟云学术

Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies

Author:

Tran K. T.¹^ORCID,McMenamin Ú. C.¹^ORCID,Hicks B.¹,Murchie P.²,Thrift A. P.³,Coleman H. G.¹⁴,Iversen L.²,Johnston B. T.⁵,Lee A. J.⁶,Cardwell C. R.¹

Affiliation:

1. Cancer Epidemiology and Health Services Research Group; Centre for Public Health; Queen's University Belfast; Belfast UK

2. Academic Primary Care; Institute of Applied Health Sciences; University of Aberdeen; Aberdeen UK

3. Section of Epidemiology and Population Sciences; Department of Medicine; Baylor College of Medicine; Houston TX USA

4. Centre for Cancer Research and Cell Biology; Queen's University Belfast; Belfast UK

5. Belfast Health and Social Care Trust; Belfast UK

6. Medical Statistics Team; Institute of Applied Health Sciences; University of Aberdeen; Aberdeen UK

Funder

Queen's University Belfast

University of Aberdeen

Vietnam International Education Cooperation Department

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

Reference37 articles.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Exploring and understanding adverse effect of Proton Pump Inhibitors;Hospital Pharmacology - International Multidisciplinary Journal;2024